Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat.com 3 Undervalued Names Too Cheap to IgnoreAuthored by Nathan Reiff. Publication Date: 3/7/2026. 
What You Need to Know - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
Highly publicized growth trajectories of some of the biggest companies may make it seem like 2026 is not a prime time for a value strategy. Still, several sizable firms are trading at attractive valuations and offer potential for share-price appreciation alongside fundamental growth. The companies below represent potential value plays, with metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits, such as compelling dividends or promising new product developments. While value opportunities can be harder to find when many companies have regained investor attention — and some that appear cheap have deteriorating operations or other red flags — well-established, stable names can still present value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Although shares have climbed more than 28% in the last year, bringing Merck's market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45, well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings climb by nearly 10% in the coming year and has a 5% additional upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which was approved for subcutaneous injection by the European Commission in late 2025. Keytruda generated about $8.4 billion in sales in Q4 2025, up nearly 7% year-over-year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base. That growth should help Merck as it prepares for Keytruda's patent expiry in 2028. Merck's portfolio is broadening, including recent phase 3 trial results for clesrovimab-cfor (Enflonsia), a treatment for RSV in young children. At the same time, the company is reorganizing its human health business into two separate units to better position itself to grow non-oncology sales as Keytruda approaches patent expiration. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have fallen about 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company posted modest year-over-year declines in organic net sales and consumption, and adjusted earnings per share (EPS) fell 13% over the same period. The company has not yet realized meaningful margin improvement despite initiating cost-saving measures. The near term will likely remain challenging for the iconic brand, as fiscal-year guidance is weak overall. Still, improvements in the supply chain and strong brand loyalty — particularly for premium offerings — should provide some protection. A shifting tariff landscape may also ease some of the external pressure the company faces. On top of that, Campbell's remains a notable dividend play, with a yield of 5.9%, though its payout ratio is fairly high at over 80%. Moreover, Campbell's P/E ratio of 13.5 is the lowest it has been in about four years. These factors may convince some investors that the stock is worth the risk despite caution among Wall Street analysts. A Recent US Foods Rally May Continue, and Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has seen a strong run: shares climbed about 33% in the last year. Its P/E ratio sits at 31.6. Fundamentally, US Foods is making important strides. The company reported improved profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year-over-year. Better inventory management and reductions in cost of goods sold are helping the firm gain traction. With a $4 billion capital deployment strategy in place, US Foods is well-positioned to maintain revenue momentum and continue its upward trend in adjusted EBITDA. Analysts view USFD as a Moderate Buy based on 11 Buys and 2 Holds, with roughly 15% upside potential.
| 
